Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 28

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
 and results of manufacturing processes, may be approximately $1.8
million and such payments may be made over up to a three-year
period.

11.
SEGMENT INFORMATION

We
follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are
determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating
decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results
of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable
segments, each with different operating and potential revenue generating characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics,
and (iii) Other. The following represents selected financial information for our segments for the three and nine months ended July 31,
2025 and 2024 and as of July 31, 2025 and October 31, 2024 (in thousands):

 SCHEDULE OF SEGMENT INFORMATION

    2025  
    2024  
    2025  
    2024 

    For
    the Three Months Ended July 31,  
    For
    the Nine Months Ended  July 31, 

    2025  
    2024  
    2025  
    2024 
  
    Net
    loss: 

    Cancer
    Vaccines 
    $(1,298) 
    $(2,160) 
    $(5,195) 
    $(5,628)
  
    CAR-T
    Therapeutics 
     (973) 
     (1,145) 
     (3,074) 
     (4,115)
  
    Other 
     (9) 
     (10) 
     (37) 
     (42)
  
    Total 
    $(2,280) 
    $(3,315) 
    $(8,306) 
    $(9,785)
  
    Net
    loss 
    $(2,280) 
    $(3,315) 
    $(8,306) 
    $(9,785)

    Total
    operating costs and expenses 
    $2,436  
    $3,592  
    $8,825  
    $10,668 
  
    Less